Akathisia, or quivering of the muscles, is a debilitating side effect often experienced by patients with schizophrenia who are prescribed such antipsychotics.
This study is one of two phase II clinical trials in Acadia’s program using ACP-103 adjunctively with other antipsychotic drugs to provide an improved therapy for schizophrenia patients.
In addition to this study, Acadia is currently conducting a phase II trial with up to 400 patients, which is designed to evaluate the ability of ACP-103 to improve both the efficacy and safety profile of current antipsychotic drugs.
“We are encouraged by the ability of ACP-103 to treat haloperidol-induced akathisia in patients with schizophrenia,” said Dr Uli Hacksell, Acadia’s CEO. “This study is an important demonstration of our ACP-103 adjunctive therapy approach to improve the quality of care for patients suffering from schizophrenia.”